<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="nihpa"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC4377066/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377066/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="JAMA"><meta name="citation_title" content="Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia"><meta name="citation_authors" content="Dr. Barthelemy Diouf, Dr. Kristine R. Crews, Dr. Glen Lew, Ms. Deqing Pei, Dr. Cheng Cheng, Dr. Ju Bao, Dr. Jie J. Zheng, Dr. Wenjian Yang, Dr. Yiping Fan, Dr. Heather E. Wheeler, Ms. Claudia Wing, Shannon M. Delaney, Dr. Masaaki Komatsu, Dr. Steven W. Paugh, Dr. Joseph Robert McCorkle, Dr. Xiaomin Lu, Dr. Naomi J. Winick, Dr. William L. Carroll, Dr. Mignon L. Loh, Dr. Stephen P. Hunger, Dr. Meenakshi Devidas, Dr. Ching-Hon Pui, Dr. M. Eileen Dolan, Dr. Mary V. Relling, Dr. William E. Evans"><meta name="citation_date" content="24 February 2015"><meta name="citation_issue" content="8"><meta name="citation_volume" content="313"><meta name="citation_firstpage" content="815"><meta name="citation_doi" content="10.1001/jama.2015.0894"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC4377066/?report=abstract"><meta name="citation_pmid" content="25710658"><meta name="DC.Title" content="Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="NIH Public Access"><meta name="DC.Contributor" content="Dr. Barthelemy Diouf"><meta name="DC.Contributor" content="Dr. Kristine R. Crews"><meta name="DC.Contributor" content="Dr. Glen Lew"><meta name="DC.Contributor" content="Ms. Deqing Pei"><meta name="DC.Contributor" content="Dr. Cheng Cheng"><meta name="DC.Contributor" content="Dr. Ju Bao"><meta name="DC.Contributor" content="Dr. Jie J. Zheng"><meta name="DC.Contributor" content="Dr. Wenjian Yang"><meta name="DC.Contributor" content="Dr. Yiping Fan"><meta name="DC.Contributor" content="Dr. Heather E. Wheeler"><meta name="DC.Contributor" content="Ms. Claudia Wing"><meta name="DC.Contributor" content="Shannon M. Delaney"><meta name="DC.Contributor" content="Dr. Masaaki Komatsu"><meta name="DC.Contributor" content="Dr. Steven W. Paugh"><meta name="DC.Contributor" content="Dr. Joseph Robert McCorkle"><meta name="DC.Contributor" content="Dr. Xiaomin Lu"><meta name="DC.Contributor" content="Dr. Naomi J. Winick"><meta name="DC.Contributor" content="Dr. William L. Carroll"><meta name="DC.Contributor" content="Dr. Mignon L. Loh"><meta name="DC.Contributor" content="Dr. Stephen P. Hunger"><meta name="DC.Contributor" content="Dr. Meenakshi Devidas"><meta name="DC.Contributor" content="Dr. Ching-Hon Pui"><meta name="DC.Contributor" content="Dr. M. Eileen Dolan"><meta name="DC.Contributor" content="Dr. Mary V. Relling"><meta name="DC.Contributor" content="Dr. William E. Evans"><meta name="DC.Date" content="2015 Feb 24"><meta name="DC.Identifier" content="10.1001/jama.2015.0894"><meta name="DC.Language" content="en"><meta property="og:title" content="Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia"><meta property="og:type" content="article"><meta property="og:description" content="With cure rates of childhood acute lymphoblastic leukemia (ALL) exceeding 85%, there is compelling need to mitigate treatment toxicities that can compromise quality of life. Peripheral neuropathy is the major dose-limiting toxicity of the microtubule ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377066/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><meta name="ncbi_feature" content="associated_data"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC4377066/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC4377066/pdf/nihms667277.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE8C2C6ADD580B110000000002EA01AD.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-ncbiexternallink-4"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4377066%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox" type="text"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a></li><li class="accid">PMC4377066</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-hhspa.png" alt="Logo of nihpa" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,57,255,75" alt="About Author manuscripts" title="About Author manuscripts" href="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html"><area shape="rect" coords="256,57,500,75" alt="Submit a manuscript" title="Submit a manuscript" href="https://www.nihms.nih.gov/" ref="reftype=publisher&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="0,0,499,74" alt="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" title="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" href="https://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref="reftype=publisher&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">JAMA</a></span>. Author manuscript; available in PMC 2015 Aug 24.</div><div></div><div>Published in final edited form as:</div><div style="margin-left:1em"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=25710658" target="pmc_ext" ref="reftype=publisher&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access"><span class="cit">JAMA. 2015 Feb 24; 313(8): 815–823. </span></a></div> <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1001%2Fjama.2015.0894" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1001/jama.2015.0894</a></span></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC4377066</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS667277</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/25710658">25710658</a></div></div></div></div><h1 class="content-title">Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Diouf%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Barthelemy Diouf</a>, PharmD, PhD, <a href="/pubmed/?term=Crews%20KR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Kristine R. Crews</a>, PharmD, <a href="/pubmed/?term=Lew%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Glen Lew</a>, MD, <a href="/pubmed/?term=Pei%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Ms. Deqing Pei</a>, MS, <a href="/pubmed/?term=Cheng%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Cheng Cheng</a>, PhD, <a href="/pubmed/?term=Bao%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Ju Bao</a>, PhD, <a href="/pubmed/?term=Zheng%20JJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Jie J. Zheng</a>, PhD, <a href="/pubmed/?term=Yang%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Wenjian Yang</a>, PhD, <a href="/pubmed/?term=Fan%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Yiping Fan</a>, PhD, <a href="/pubmed/?term=Wheeler%20HE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Heather E. Wheeler</a>, PhD, <a href="/pubmed/?term=Wing%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Ms. Claudia Wing</a>, MS, <a href="/pubmed/?term=Delaney%20SM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Shannon M. Delaney</a>, <a href="/pubmed/?term=Komatsu%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Masaaki Komatsu</a>, MD, PhD, <a href="/pubmed/?term=Paugh%20SW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Steven W. Paugh</a>, PhD, <a href="/pubmed/?term=McCorkle%20JR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Joseph Robert McCorkle</a>, PhD, <a href="/pubmed/?term=Lu%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Xiaomin Lu</a>, PhD, <a href="/pubmed/?term=Winick%20NJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Naomi J. Winick</a>, MD, <a href="/pubmed/?term=Carroll%20WL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. William L. Carroll</a>, MD, <a href="/pubmed/?term=Loh%20ML%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Mignon L. Loh</a>, MD, <a href="/pubmed/?term=Hunger%20SP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Stephen P. Hunger</a>, MD, <a href="/pubmed/?term=Devidas%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Meenakshi Devidas</a>, PhD, <a href="/pubmed/?term=Pui%20CH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Ching-Hon Pui</a>, MD, <a href="/pubmed/?term=Dolan%20ME%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. M. Eileen Dolan</a>, PhD, <a href="/pubmed/?term=Relling%20MV%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. Mary V. Relling</a>, PharmD, and  <a href="/pubmed/?term=Evans%20WE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25710658">Dr. William E. Evans</a>, PharmD.<sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140661446583296_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140661446583296_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140661446583296_ai" style="display:none"><div class="fm-affl" id="A1" lang="en">Hematological Malignancies Program, and Department of Pharmaceutical Sciences (Drs Diouf, Crews, Yang, Paugh, McCorkle, Relling and Evans), Department of Biostatistics (Ms Pei and Dr Cheng), Department of Structural Biology (Drs Bao and Zheng), Department of Computational Biology (Dr Fan), Department of Oncology (Dr Pui), St. Jude Children’s Research Hospital, Memphis, Tennessee; Aflac Cancer and Blood Disorders Center (Dr Lew), Children’s Healthcare of Atlanta/Emory University, Atlanta, Georgia; Section of Hematology/Oncology Department of Medicine (Drs Wheeler, Komatsu, Dolan and Ms Wing), University of Chicago, Illinois; Department of Biostatistics (Drs Lu and Devidas), Colleges of Medicine, Public Health &amp; Health Professions, University of Florida, Gainesville, Florida; Division of Pediatric Hematology/Oncology (Dr Winick), University of Texas Southwestern School of Medicine, Dallas, Texas; New York University Cancer Institute (Dr Carroll) New York, New York; Department of Pediatrics (Dr Loh), University of California School of Medicine, San Francisco, California; Section of Pediatric Hematology/Oncology/Bone Marrow Transplantation and Center for Cancer and Blood Disorders (Dr Hunger), University of Colorado School of Medicine, Children’s Hospital Colorado, Aurora, Colorado</div><div id="FN1"><sup>*</sup>Correspondence: <a href="mailto:dev@null" data-email="gro.edujts@snave.mailliw" class="oemail">gro.edujts@snave.mailliw</a>; Dr William E. Evans, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA; Phone: (901) 495-6850; Fax: (901) 595-8869</div></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="permissions fm-panel half_rhythm hide" id="idm140661446583296_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>The publisher's final edited version of this article is available  at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=25710658" target="pmc_ext" ref="reftype=publisher&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">JAMA</a></div><div>See other articles in PMC that <a href="/pmc/articles/PMC4377066/citedby/">cite</a> the published article.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="ui-helper-clearfix" id="ui-ncbiinpagenav-heading-3">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supplemental Materials.</strong></div><div><a href="/pmc/articles/PMC4377066/bin/NIHMS667277-supplement-Supplemental_Materials.pdf" data-ga-action="click_feat_suppl">NIHMS667277-supplement-Supplemental_Materials.pdf</a><span style="color:gray"> (680K)</span></div><div class="small guid">GUID:&nbsp;D1451E31-CBEC-4CDA-8652-9FFCEE00C80E</div></div></dd></dl></div><div id="idm140661515613664" class="tsec sec" lang="en"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140661515613664title">Abstract</h2><!--article-meta--><div><div id="S1" class="sec sec-first"><h3 id="S1title">Importance</h3><p id="P1" class="p p-first-last">With cure rates of childhood acute lymphoblastic leukemia (ALL) exceeding 85%, there is compelling need to mitigate treatment toxicities that can compromise quality of life. Peripheral neuropathy is the major dose-limiting toxicity of the microtubule inhibitor vincristine, an anticancer agent given to every child with ALL.</p></div><div id="S2" class="sec"><h3 id="S2title">Objective</h3><p id="P2" class="p p-first-last">Identify genetic germline variants associated with the occurrence or severity of vincristine-induced peripheral neuropathy in children with ALL.</p></div><div id="S3" class="sec"><h3 id="S3title">Design, Setting and Participants</h3><p id="P3" class="p p-first-last">All patients had been enrolled in one of two prospective clinical trials for childhood ALL that included treatment with 36–39 doses of vincristine. Genome-wide single nucleotide polymorphism (SNP) analysis and vincristine-induced peripheral neuropathy were assessed in all patients from whom DNA was available (n=321 patients); 222 patients (median age at 6.0 years, range 0.1–18.8 years) enrolled between 1994–1998 on the St. Jude Children’s Research Hospital protocol Total XIIIB (St. Jude cohort) with toxicity followed through January 2001, and 99 patients (median age 11.4 years, range 3.0–23.8 years) enrolled between 2007–2010 on the Children’s Oncology Group protocol AALL0433 (COG cohort) with toxicity followed through May 2011. Human leukemia cells and induced pluripotent stem cell neurons were used to assess the effects of lower <em>CEP72</em> expression on vincristine sensitivity.</p></div><div id="S4" class="sec"><h3 id="S4title">Exposures</h3><p id="P4" class="p p-first-last">Treatment with vincristine at a dosage of 1.5 or 2.0 mg/m<sup>2</sup> as a component of protocol directed chemotherapy for childhood ALL.</p></div><div id="S5" class="sec"><h3 id="S5title">Main Outcomes and Measures</h3><p id="P5" class="p p-first-last">Vincristine-induced peripheral neuropathy was assessed at each clinic visit using the National Cancer Institute Common Terminology Criteria for Adverse Events and prospectively graded as mild (grade 1), moderate (grade 2), serious/disabling (grade 3), or life-threatening (grade 4).</p></div><div id="S6" class="sec"><h3 id="S6title">Results</h3><p id="P6" class="p p-first-last">Grade 2–4 vincristine-induced neuropathy during continuation therapy occurred in 28.8% of patients (n=64 of 222) in the St. Jude cohort and in 22.2% of patients (n=22 of 99) in the COG cohort. A SNP in the promoter region of the <em>CEP72</em> gene, which encodes a centrosomal protein involved in microtubule formation, had a significant association with vincristine neuropathy (meta <em>p</em> =6.3 × 10<sup>−9</sup>). This SNP had a minor allele frequency of 37% (235/642), with 50 of 321 patients (16%, 95% CI 11.6%–19.5%) homozygous for the risk allele (TT at rs924607). Among patients with the high-risk <em>CEP72</em> genotype (TT at rs924607), 28 of 50 patients (56%, 95% CI 41.2–70.0) developed at least one episode of grade 2–4 neuropathy, a higher rate than in patients with the <em>CEP72</em> CC or CT genotype (58 of 271 patients; 21.4%, 95% CI 16.9–26.7); <em>p</em>=2.4×10<sup>−6</sup>. The severity (grade) of neuropathy was greater (2.4-fold by Poisson regression (<em>p</em>&lt;0.0001), 2.7-fold based on mean grade of neuropathy (1.23 [95% CI 0.74 – 1.72] versus 0.45 [95% CI 0.3 – 0.6]; t test p=0.004)) in patients homozygous for the <em>CEP72</em> risk allele (TT genotype), compared to patients with the CC or CT genotype. The <em>CEP72</em> promoter SNP was shown to create a binding site for a transcriptional repressor causing lower mRNA expression, and reducing <em>CEP72</em> expression in human neurons and leukemia cells increased their sensitivity to vincristine.</p></div><div id="S7" class="sec sec-last"><h3 id="S7title">Conclusions</h3><p id="P7" class="p p-first-last">In this preliminary study of children with ALL, an inherited polymorphism in the promoter region of <em>CEP72</em> was associated with increased risk and severity of vincristine-related peripheral neuropathy. If replicated in additional populations, this finding may provide a basis for safer dosing of this widely prescribed anticancer agent.</p></div></div></div><div id="S8" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S8title">Introduction</h2><p id="P8" class="p p-first">Cancer remains the leading cause of death by disease in US children, despite major advances in the last 20 years. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and as cure rates have surpassed 85%<sup><a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760755">1</a>,<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760773">2</a></sup>, it becomes increasingly important to mitigate acute and chronic toxicities of treatment that adversely affect quality of life and longevity. Vincristine is one of the most widely used and effective anticancer agents for treating leukemias, lymphomas, brain tumors and solid tumors in both adults and children<sup><a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760754">1</a>,<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760759">2</a></sup> and is administered multiple times as part of treatment protocols for every child with ALL and for children with neuroblastoma, Wilm’s tumor, rhabdomyosarcoma, Ewing sarcoma, and retinoblastoma<sup><a href="#R3" rid="R3" class=" bibr popnode">3</a></sup></p><p id="P9">Vincristine exerts its cytotoxic effects by interfering with microtubule formation and mitotic spindle dynamics, leading to mitotic arrest and cell death<sup><a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760761">4</a>–<a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760758">6</a></sup>. The dose-limiting toxicity of vincristine is peripheral neuropathy<sup><a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760766">7</a>,<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760775">8</a></sup>, characterized by neuropathic pain and sensory and motor dysfunction (e.g., impaired manual dexterity, balance and deep tendon reflexes, and altered gait). A substantial percentage of patients develop neuropathy that causes considerable morbidity and often disrupts curative treatment<sup><a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760771">9</a></sup>. Currently, there are no reliable means of identifying patients at high risk of vincristine-induced neuropathy nor strategies to mitigate this drug toxicity. Although prior studies have documented racial differences in the incidence of vincristine neuropathy, candidate gene studies have failed to identify consistent genetic variants associated with an increased risk of vincristine-induced neuropathy<sup><a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760752">9</a>–<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760763">12</a></sup>.</p><p id="P10" class="p p-last">To determine whether there are genetic polymorphisms associated with vincristine-induced neuropathy, we performed a genome-wide association study (GWAS) in two independent cohorts of children receiving protocol-defined treatment for acute lymphoblastic leukemia (ALL).</p></div><div id="S9" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S9title">Methods</h2><div id="S10" class="sec sec-first"><h3 id="S10title">Patients and treatment regimens</h3><p id="P11" class="p p-first">Two independent patient cohorts were treated either by St. Jude Children’s Research Hospital or the Children’s Oncology Group (COG) according to contemporary IRB-approved ALL protocols that prospectively assessed and graded vincristine neuropathy according to National Cancer Institute (NCI) criteria. We analyzed all consenting patients who had germline DNA available for genome-wide SNP analyses in May 2011. The first cohort included children with newly-diagnosed ALL enrolled and treated on the St. Jude Total XIIIB protocol <sup><a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760757">13</a>–<a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760777">15</a></sup>(provided in <a href="#SD1" rid="SD1" class=" supplementary-material">online Supplement</a>). The second cohort included patients with relapsed ALL enrolled on the COG AALL0433 protocol (http://clinicaltrials.gov/show/<a id="__tag_559192256" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00381680" ref="reftype=extlink-clinical-trial&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00381680","term_id":"NCT00381680"}}</span>NCT00381680</a>). Written informed consent was obtained from patients or their guardians and assent from patients (as appropriate).</p><p id="P12">The St. Jude Total XIIIB protocol was divided into 3 phases: 8 weeks of remission induction therapy, 2 weeks of consolidation therapy, and 120 weeks of continuation therapy (including a re-induction phase at weeks 16–21). Vincristine was administered as a component of combination chemotherapy during the induction and continuation phases of therapy at a dosage of 1.5 mg/m<sup>2</sup> with a maximum dose of 2 mg. Altogether, St. Jude patients were scheduled to receive a total of 36 vincristine doses. Consecutive patients were enrolled between August 1994 and July 1998, and toxicity was followed through 2001.</p><p id="P13">The COG AALL0433 protocol was a cooperative group wide, Phase III randomized study of intensive therapy for patients with recurrent childhood B-precursor ALL, including late bone marrow or combined relapse (≥36 months from diagnosis), or early (&lt; 18 months from diagnosis) isolated extramedullary relapse in the central nervous system or testes (http://clinicaltrials.gov/show/<a id="__tag_559192255" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00381680" ref="reftype=extlink-clinical-trial&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00381680","term_id":"NCT00381680"}}</span>NCT00381680</a>). COG AALL0433 treatment was divided into induction, intensification (with a re-induction phase at weeks 28–32 or 29–33) and continuation phases. Vincristine was administered as a component of combination chemotherapy during the induction, intensification, re-induction and continuation phases of therapy; a total of 39 doses of vincristine were scheduled to be given per this protocol. Patients were randomly assigned to receive a vincristine dosage of 1.5 mg/m<sup>2</sup> with a maximum dose of 2 mg (Group A) or 2 mg/m<sup>2</sup> with a maximum dose of 2.5 mg (Group B). Group B treatment and the vincristine dose randomization were permanently suspended by COG in 2010, due to the high incidence of peripheral neuropathy, most prominently in patients ≥13 years of age. Patients were enrolled between March 2007 and September 2010 at the time of the suspension of Group B treatment, and toxicity was followed through May 2011.</p><p id="P14" class="p p-last">As part of required clinical trial adverse event monitoring, children in both cohorts were prospectively assessed for the presence of peripheral neuropathy via physical examination by the treating oncologist at each clinic visit during treatment<sup><a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760767">16</a>,<a href="#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760770">17</a></sup>. Children in the St. Jude cohort were assessed for toxicity weekly throughout all phases of therapy. Children in the COG cohort were assessed for toxicity weekly throughout the first year of therapy, and monthly thereafter. For these analyses children on St. Jude Total XIIIB were graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 1.0 and those in the COG cohort according to a modified “Balis” scale for neuropathy, which is a modification of the NCI CTCAE version 2.0. (<a href="#SD1" rid="SD1" class=" supplementary-material">eTables 1, 2</a>). Both scales classify neuropathy events as mild (grade 1), moderate (grade 2), serious/disabling (grade 3), or life-threatening (grade 4)<sup><a href="#R18" rid="R18" class=" bibr popnode">18</a></sup>. Those with Grades 2, 3 or 4 motor and/or sensory neuropathy were considered as neuropathy cases in our analyses. There were no neuropathy related deaths (Grade 5). Follow-up for the St. Jude cohort continued through January 2001; follow-up for the COG cohort continued through May 2011.</p></div><div id="S11" class="sec"><h3 id="S11title">Genotyping</h3><p id="P15" class="p p-first">Germline DNA (500 ng) was extracted from normal peripheral blood leukocytes, digested with restriction enzymes, amplified, labeled, and hybridized to the Affymetrix GeneChip Human Mapping 500K array (532552 SNPs) or the SNP 6.0 array (906600 SNPs) (Affymetrix, Santa Clara, CA). SNPs were excluded if genotyping call rates were less than 95% and if the minor allele frequency less than 1%. (See <a href="#SD1" rid="SD1" class=" supplementary-material">Supplemental material</a> for additional details). SNP imputation was carried out using Mach/1.0.15<sup><a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760753">19</a></sup>. The total number of SNPs that were imputed was 21764463 (See <a href="#SD1" rid="SD1" class=" supplementary-material">supplemental material</a> for additional details).</p><p id="P16" class="p p-last">Race was genetically determined following a method previously described<sup><a href="#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760776">20</a></sup>. Briefly, the genetic ancestry estimates were determined by applying STRUCTURE (version 2.2.3) using HapMap project data as references (See <a href="#SD1" rid="SD1" class=" supplementary-material">Supplemental material</a> for additional details). SNP genotype data for HapMap cell were downloaded from release 22 on the International HapMap Project website (<a href="http://www.HapMap.org" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.HapMap.org</a>).</p></div><div id="S12" class="sec"><h3 id="S12title">Cellular analyses</h3><p id="P17" class="p p-first-last">The human pre-B leukemia cell line NALM6, the human T-lineage leukemia cell line CEM and the neuroblastoma cell line SH-SY5Y were cultured in RPMI-1640 medium containing 2mM glutamine and 10% (vol/vol) FBS at 37°C with 5% CO2. iCell neurons derived from human induced pluripotent stem cells were obtained from Cellular Dynamics International (Madison, WI) and maintained per manufacturer’s protocol. Primary ALL cells were isolated by applying a Ficoll-Hypaque gradient to bone marrow aspirates obtained at diagnosis (with a median of 97% blast cells). <em>CEP72</em> expression was impaired by using short hairpin RNA (shRNA). In vitro drug sensitivity of primary ALL cells and of Nalm6 and CEM cell lines was determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazoliumbromide) assay, as previously reported<sup><a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760762">21</a></sup>. The drug concentration lethal to 50 percent of the leukemia cells (LC<sub>50</sub>) was used as the measure of sensitivity to vincristine. Vincristine-induced neurotoxicity in iCell neurons was determined by individual cell measurements of total neurite outgrowth, number of processes and number of branches in 1000 cells for each replicate experiment. Luciferase assays to measure <em>CEP72</em> expression were performed as described in the <a href="#SD1" rid="SD1" class=" supplementary-material">supplemental methods</a>. Gene expression of HapMap cells measured by the Affymetrix GeneChip Human Exon 1.0 ST Array was downloaded from the website (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=<a id="__tag_438760778" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE7761" ref="/geo/query/acc.cgi?acc=GSE7761"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE7761","term_id":"7761"}}</span>GSE7761</a>.)</p></div><div id="S13" class="sec sec-last"><h3 id="S13title">Statistical analysis</h3><p id="P18" class="p p-first">Analyses were conducted using R (<a href="http://www.r-project.org/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.r-project.org/</a>) and SAS (SAS Institute, Cary, NC). Weighted logistic regression model fitting for recurrent events was used to test the associations between SNP genotypes and the phenotype of peripheral neuropathy (i.e., occurrence of grade 2 or higher vincristine-induced neuropathy during continuation therapy), including cumulative vincristine dosage and genetically determined ancestry as covariates, as previously described.<sup><a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760772">15</a></sup> See <a href="#SD1" rid="SD1" class=" supplementary-material">supplemental materials</a> for additional statistical details. After filtering out SNPs with a call rate &lt;95% (SNP call rate is the percentage of patients who have a confident genotype call for each SNP according to Affymetrix quality control criteria) and minor allele frequency &lt;1%; the remaining SNPs (484,623 typed SNPs and 1,091,393 imputed SNPs) were assessed in a GWAS for their association with vincristine-induced neuropathy, in St. Jude and COG cohorts separately using weighted logistics regression models, then combined by pooling the p values from the two cohorts via Fisher’s method. All <em>p</em>-values were computed using two-sided tests; statistical significance was determined at the genome-wide significance level 5×10<sup>−8</sup></p><p id="P19" class="p p-last">Post-GWAS analyses focusing on the <em>CEP72</em> SNP rs924607 were performed as follows: the relationship between the time to first episode and genotype was analyzed using cumulative incidence function estimates<sup><a href="#R22" rid="R22" class=" bibr popnode">22</a></sup> and Gray’s test<sup><a href="#R23" rid="R23" class=" bibr popnode">23</a></sup>, Cox regression and accelerated failure time regression<sup><a href="#R22" rid="R22" class=" bibr popnode">22</a></sup>, with cumulative dose and genetic ancestry as covariates. The relationship between the cumulative vincristine dosage at the first episode of toxicity and genotype was analyzed by Cox regression with genetically determined ancestry as a covariate. The relationship between severity (grade) of toxicity at the first episode and genotype was analyzed by Poisson regression model with cumulative dose and genetic ancestry as covariates. Student’s t test was used to examine the differences in luciferase reporter activity. A linear regression model was used to test the association between vincristine sensitivity (LC<sub>50</sub>) and the SNP genotype in primary ALL cells. In post-GWAS analyses and laboratory experiments, all tests were two-sided and significance was determined at the 0.05 level.</p></div></div><div id="S14" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S14title">Results</h2><div id="S15" class="sec sec-first"><h3 id="S15title">Patient population</h3><p id="P20" class="p p-first">Genome-wide SNP analysis and vincristine-induced neuropathy were assessed in 321 patients enrolled on two ALL treatment protocols. Of 247 consecutive patients enrolled on the St. Jude Total XIIIB protocol, 222 patients with newly diagnosed ALL (median age at diagnosis 6.0 years, range 0.1–18.8 years) had germline DNA available for analysis and were included in this study (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 1</a>). Of the 137 patients who were enrolled in the COG AALL0433 protocol, 99 patients with relapsed ALL (median age at diagnosis 11.4 years, range 3.0–23.8 years) had germline DNA available for analysis and were included in this study (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 2</a>).</p><p id="P21" class="p p-last">The demographic and clinical characteristics of these 321 patients are summarized in <a href="/pmc/articles/PMC4377066/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table1</span></a> and for each cohort in <a href="#SD1" rid="SD1" class=" supplementary-material">eTables 3 and 4</a>.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p19">Characteristics of patients in the combined cohort of St. Jude and COG patients assessed for vincristine neuropathy.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140661443608160" class="xtable"><table frame="box" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="3" colspan="1" valign="bottom" align="left">Characteristics<sup>a</sup></th><th colspan="5" rowspan="1" valign="bottom" align="center">Vincristine Neuropathy
<hr></th><th rowspan="3" colspan="1" valign="bottom" align="center">P value<sup>d</sup></th></tr><tr><th colspan="4" rowspan="1" valign="bottom" align="center">No. Patients (%)
<hr></th><th rowspan="1" colspan="1" valign="bottom" align="center">No. Episodes of Vincristine Neuropathy
<hr></th></tr><tr><th rowspan="1" colspan="1" valign="bottom" align="center">Total Patients (n=321)<sup>b</sup></th><th rowspan="1" colspan="1" valign="bottom" align="center">None to Grade 1</th><th rowspan="1" colspan="1" valign="bottom" align="center">1 episode of Grade 2–4</th><th rowspan="1" colspan="1" valign="bottom" align="center">2 or more episodes of Grade 2–4</th><th rowspan="1" colspan="1" valign="bottom" align="center">Episodes of Grade 2–4<sup>c</sup></th></tr></thead><tbody><tr><td colspan="7" rowspan="1" valign="bottom" align="left"><strong>Age at diagnosis, y</strong>
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> &lt; 1</td><td rowspan="1" colspan="1" valign="top" align="center">8 (2.5)</td><td rowspan="1" colspan="1" valign="top" align="center">7</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">0.03</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> 1–10</td><td rowspan="1" colspan="1" valign="top" align="center">192 (59.8)</td><td rowspan="1" colspan="1" valign="top" align="center">137</td><td rowspan="1" colspan="1" valign="top" align="center">34</td><td rowspan="1" colspan="1" valign="top" align="center">21</td><td rowspan="1" colspan="1" valign="top" align="center">103</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> &gt; 10</td><td rowspan="1" colspan="1" valign="top" align="center">121 (37.7)</td><td rowspan="1" colspan="1" valign="top" align="center">91</td><td rowspan="1" colspan="1" valign="top" align="center">16</td><td rowspan="1" colspan="1" valign="top" align="center">14</td><td rowspan="1" colspan="1" valign="top" align="center">84</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td colspan="7" rowspan="1" valign="bottom" align="left">
<hr></td></tr><tr><td colspan="7" rowspan="1" valign="bottom" align="left"><strong>Sex</strong>
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Male</td><td rowspan="1" colspan="1" valign="top" align="center">187 (58.3)</td><td rowspan="1" colspan="1" valign="top" align="center">142</td><td rowspan="1" colspan="1" valign="top" align="center">29</td><td rowspan="1" colspan="1" valign="top" align="center">16</td><td rowspan="1" colspan="1" valign="top" align="center">88</td><td rowspan="1" colspan="1" valign="top" align="center">0.02</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Female</td><td rowspan="1" colspan="1" valign="top" align="center">134 (41.7)</td><td rowspan="1" colspan="1" valign="top" align="center">93</td><td rowspan="1" colspan="1" valign="top" align="center">22</td><td rowspan="1" colspan="1" valign="top" align="center">19</td><td rowspan="1" colspan="1" valign="top" align="center">100</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td colspan="7" rowspan="1" valign="bottom" align="left">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>Genetically-determined Ancestry</strong></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td colspan="7" rowspan="1" valign="bottom" align="left">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> European</td><td rowspan="1" colspan="1" valign="top" align="center">209 (65.1)</td><td rowspan="1" colspan="1" valign="top" align="center">156</td><td rowspan="1" colspan="1" valign="top" align="center">29</td><td rowspan="1" colspan="1" valign="top" align="center">24</td><td rowspan="1" colspan="1" valign="top" align="center">123</td><td rowspan="1" colspan="1" valign="top" align="center">0.002</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> African</td><td rowspan="1" colspan="1" valign="top" align="center">43 (13.4)</td><td rowspan="1" colspan="1" valign="top" align="center">33</td><td rowspan="1" colspan="1" valign="top" align="center">8</td><td rowspan="1" colspan="1" valign="top" align="center">2</td><td rowspan="1" colspan="1" valign="top" align="center">15</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Asian</td><td rowspan="1" colspan="1" valign="top" align="center">2 (0.6)</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Hispanic</td><td rowspan="1" colspan="1" valign="top" align="center">44 (13.7)</td><td rowspan="1" colspan="1" valign="top" align="center">30</td><td rowspan="1" colspan="1" valign="top" align="center">7</td><td rowspan="1" colspan="1" valign="top" align="center">7</td><td rowspan="1" colspan="1" valign="top" align="center">36</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Other</td><td rowspan="1" colspan="1" valign="top" align="center">23 (7.2)</td><td rowspan="1" colspan="1" valign="top" align="center">15</td><td rowspan="1" colspan="1" valign="top" align="center">6</td><td rowspan="1" colspan="1" valign="top" align="center">2</td><td rowspan="1" colspan="1" valign="top" align="center">13</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td colspan="7" rowspan="1" valign="bottom" align="left">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>Cumulative vincristine dosage (mg/m2), median [range]</strong></td><td rowspan="1" colspan="1" valign="top" align="center">47 [2–120]</td><td rowspan="1" colspan="1" valign="top" align="center">46 [2–120]</td><td rowspan="1" colspan="1" valign="top" align="center">51 [8–92]</td><td rowspan="1" colspan="1" valign="top" align="center">49 [10–120]</td><td rowspan="1" colspan="1" valign="top" align="center">52 [22–120]</td><td rowspan="1" colspan="1" valign="top" align="center">0.28</td></tr></tbody></table></div><div id="largeobj_idm140661443608160" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC4377066/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN1"><sup>a</sup>Data are presented as Number (%) of patients unless otherwise indicated.</div><div id="TFN2"><sup>b</sup>Cohort includes patients treated on St. Jude Total XIIIB (n=222) and on COG AALL0433 (n=99).</div><div id="TFN3"><sup>c</sup>Number of events.</div><div id="TFN4"><sup>d</sup>p values are from univariate weighted logistic regression using each episode as an observation.</div></div></div></div><div id="S16" class="sec"><h3 id="S16title">Vincristine-associated Neurotoxicity</h3><p id="P22" class="p p-first-last">Grade 2–4 vincristine-induced peripheral neuropathy during continuation therapy occurred in 28.8% (n=64 of 222) and 22.2% (n=22 of 99) of patients on the St Jude and COG protocols, respectively. Genetically-determined ancestry and vincristine cumulative dosage were the demographic or clinical characteristics significantly related to the occurrence of vincristine-induced neuropathy in each of the cohorts, as summarized in <a href="#SD1" rid="SD1" class=" supplementary-material">eTables 3 and 4</a>. Within the COG trial, the rate of vincristine-induced neuropathy was higher in the cohort of patients randomized to the higher dosage of vincristine (2.0 mg/m<sup>2</sup> with a maximum dose of 2.5 mg) compared to those randomized to the conventional dosage (1.5 mg/m<sup>2</sup> with a maximum dose of 2 mg); 19 of 48 patients (39.6%) vs 3 of 51 patients (5.9%) <em>p</em>&lt;0.0001, leading to early closure of the higher-dose treatment group of the COG protocol.</p></div><div id="S17" class="sec"><h3 id="S17title">Meta-analysis of genome-wide association results</h3><p id="P23" class="p p-first">Assessing SNPs that had a <em>p</em>-value &lt;0.05 in both cohorts and concordant effects in both populations yielded 5,051 typed SNPs and 10,195 imputed SNPs. The Manhattan plot (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigurea</a>) depicts <em>p</em>-values of SNPs from the two patient cohorts assessed via a meta-analysis. The SNPs with the lowest <em>p</em>-values for their association with vincristine-induced neuropathy in the two cohorts are summarized in <a href="/pmc/articles/PMC4377066/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a> and in <a href="#SD1" rid="SD1" class=" supplementary-material">eTable 5</a>. In a multivariate analysis that included genetically defined ancestry and cumulative dosage of vincristine, only rs924607 remained genome-wide significantly (<em>p</em>=4.7×10<sup>−8</sup>) related to the development of vincristine-induced neuropathy (<a href="/pmc/articles/PMC4377066/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">eTable 5</a>). Rs924607 is in the promoter region of the <em>CEP72</em> gene in chromosome 5 (<a href="/pmc/articles/PMC4377066/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC4377066/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140661439711040" class="figure"><a href="/pmc/articles/PMC4377066/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4377066_nihms667277f1.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms667277f1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC4377066/bin/nihms667277f1.jpg"></a></div><div id="largeobj_idm140661439711040" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4377066/figure/F1/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC4377066/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p17">Regional association plot for the rs924607 locus on chromosome 5 (blue diamond). Each SNP is plotted with respect to its chromosomal location (x axis) and the corresponding meta <em>P</em> value for association with vincristine neuropathy (left y axis). The blue line depicts the recombination rate (right y axis) at the corresponding region of chromosome 5 (x axis). SNPs are colored to indicate extent of LD with the indexed SNP (pairwise r<sup>2</sup> values from HapMap CEU). The NCBI Build 37 corresponding to the 1000 Genomes Project March 2012 reference was used.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p id="__p24">SNPs associated with the incidence of vincristine-induced neuropathy (Grades 2–4).<sup>a</sup></p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140661438638832" class="xtable"><table frame="box" rules="none" class="rendered small default_table"><thead><tr><th rowspan="2" colspan="1" valign="bottom" align="center">SNP</th><th rowspan="2" colspan="1" valign="bottom" align="center">Chr</th><th rowspan="2" colspan="1" valign="bottom" align="center">Position</th><th rowspan="2" colspan="1" valign="bottom" align="center">Nearest<br>gene</th><th rowspan="2" colspan="1" valign="bottom" align="center">Allele<br>major/<br>minor</th><th colspan="4" rowspan="1" valign="bottom" align="center">St Jude Total XIIIB
<hr></th><th colspan="4" rowspan="1" valign="bottom" align="center">COG AALL0433
<hr></th><th rowspan="1" colspan="1" valign="bottom" align="center">Meta-analysis<br>(univariate)</th><th rowspan="1" colspan="1" valign="bottom" align="center">Meta-analysis<sup>c</sup><br>(multivariate)</th></tr><tr><th rowspan="1" colspan="1" valign="bottom" align="center">MAF<br>(%)</th><th rowspan="1" colspan="1" valign="bottom" align="center">OR</th><th rowspan="1" colspan="1" valign="bottom" align="center">95% CI</th><th rowspan="1" colspan="1" valign="bottom" align="center">P-value</th><th rowspan="1" colspan="1" valign="bottom" align="center">MAF<br>(%)</th><th rowspan="1" colspan="1" valign="bottom" align="center">OR</th><th rowspan="1" colspan="1" valign="bottom" align="center">95% CI</th><th rowspan="1" colspan="1" valign="bottom" align="center">P-value</th><th rowspan="1" colspan="1" valign="bottom" align="center">P-value</th><th rowspan="1" colspan="1" valign="bottom" align="center">P-value</th></tr><tr><th colspan="9" rowspan="1" valign="bottom" align="left">
<hr></th><th colspan="6" rowspan="1" valign="bottom" align="center">
<hr></th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="center">rs924607<sup>b</sup></td><td rowspan="1" colspan="1" valign="top" align="center">5</td><td rowspan="1" colspan="1" valign="top" align="center">663093</td><td rowspan="1" colspan="1" valign="top" align="center">CEP72</td><td rowspan="1" colspan="1" valign="top" align="center">C/T</td><td rowspan="1" colspan="1" valign="top" align="center">36.7</td><td rowspan="1" colspan="1" valign="top" align="center">2.43</td><td rowspan="1" colspan="1" valign="top" align="center">1.70–3.49</td><td rowspan="1" colspan="1" valign="top" align="center">1.25×10<sup>−6</sup></td><td rowspan="1" colspan="1" valign="top" align="center">36.4</td><td rowspan="1" colspan="1" valign="top" align="center">4.1</td><td rowspan="1" colspan="1" valign="top" align="center">1.86–9.01</td><td rowspan="1" colspan="1" valign="top" align="center">0.0004</td><td rowspan="1" colspan="1" valign="top" align="center">6.33×10<sup>−9</sup></td><td rowspan="1" colspan="1" valign="top" align="center">4.68×10<sup>−8</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">rs17032980</td><td rowspan="1" colspan="1" valign="top" align="center">2</td><td rowspan="1" colspan="1" valign="top" align="center">67156247</td><td rowspan="1" colspan="1" valign="top" align="center">ETAA1</td><td rowspan="1" colspan="1" valign="top" align="center">A/G</td><td rowspan="1" colspan="1" valign="top" align="center">26.6</td><td rowspan="1" colspan="1" valign="top" align="center">3.17</td><td rowspan="1" colspan="1" valign="top" align="center">1.95–5.17</td><td rowspan="1" colspan="1" valign="top" align="center">3.67×10<sup>−6</sup></td><td rowspan="1" colspan="1" valign="top" align="center">19.2</td><td rowspan="1" colspan="1" valign="top" align="center">10.4</td><td rowspan="1" colspan="1" valign="top" align="center">2.97–36.15</td><td rowspan="1" colspan="1" valign="top" align="center">0.0002</td><td rowspan="1" colspan="1" valign="top" align="center">9.77×10<sup>−9</sup></td><td rowspan="1" colspan="1" valign="top" align="center">9.01×10<sup>−7</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">rs12786200</td><td rowspan="1" colspan="1" valign="top" align="center">11</td><td rowspan="1" colspan="1" valign="top" align="center">91618666</td><td rowspan="1" colspan="1" valign="top" align="center">MTNR1B</td><td rowspan="1" colspan="1" valign="top" align="center">C/T</td><td rowspan="1" colspan="1" valign="top" align="center">22.7</td><td rowspan="1" colspan="1" valign="top" align="center">0.23</td><td rowspan="1" colspan="1" valign="top" align="center">0.13–0.40</td><td rowspan="1" colspan="1" valign="top" align="center">1.58×10<sup>−7</sup></td><td rowspan="1" colspan="1" valign="top" align="center">20.7</td><td rowspan="1" colspan="1" valign="top" align="center">0.24</td><td rowspan="1" colspan="1" valign="top" align="center">0.08–0.76</td><td rowspan="1" colspan="1" valign="top" align="center">0.02</td><td rowspan="1" colspan="1" valign="top" align="center">2.56×10<sup>−8</sup></td><td rowspan="1" colspan="1" valign="top" align="center">6.30×10<sup>−7</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">rs4463516 <sup>b</sup></td><td rowspan="1" colspan="1" valign="top" align="center">9</td><td rowspan="1" colspan="1" valign="top" align="center">32857481</td><td rowspan="1" colspan="1" valign="top" align="center">TMEM215</td><td rowspan="1" colspan="1" valign="top" align="center">C/G</td><td rowspan="1" colspan="1" valign="top" align="center">33.6</td><td rowspan="1" colspan="1" valign="top" align="center">2.89</td><td rowspan="1" colspan="1" valign="top" align="center">1.90–4.39</td><td rowspan="1" colspan="1" valign="top" align="center">6.83×10<sup>−7</sup></td><td rowspan="1" colspan="1" valign="top" align="center">24.2</td><td rowspan="1" colspan="1" valign="top" align="center">4.94</td><td rowspan="1" colspan="1" valign="top" align="center">1.65–14.79</td><td rowspan="1" colspan="1" valign="top" align="center">0.004</td><td rowspan="1" colspan="1" valign="top" align="center">3.02×10<sup>−8</sup></td><td rowspan="1" colspan="1" valign="top" align="center">1.19×10<sup>−7</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">rs7818688 <sup>b</sup></td><td rowspan="1" colspan="1" valign="top" align="center">8</td><td rowspan="1" colspan="1" valign="top" align="center">96093258</td><td rowspan="1" colspan="1" valign="top" align="center">NDUFAF6</td><td rowspan="1" colspan="1" valign="top" align="center">C/A</td><td rowspan="1" colspan="1" valign="top" align="center">12.6</td><td rowspan="1" colspan="1" valign="top" align="center">4.26</td><td rowspan="1" colspan="1" valign="top" align="center">2.45–7.42</td><td rowspan="1" colspan="1" valign="top" align="center">3.05×10<sup>−7</sup></td><td rowspan="1" colspan="1" valign="top" align="center">14.1</td><td rowspan="1" colspan="1" valign="top" align="center">4.59</td><td rowspan="1" colspan="1" valign="top" align="center">1.35–15.59</td><td rowspan="1" colspan="1" valign="top" align="center">0.01</td><td rowspan="1" colspan="1" valign="top" align="center">4.46×10<sup>−8</sup></td><td rowspan="1" colspan="1" valign="top" align="center">5.03×10<sup>−7</sup></td></tr></tbody></table></div><div id="largeobj_idm140661438638832" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC4377066/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN5"><p id="__p25" class="p p-first-last">MAF = minor allele frequency, OR = odds ratio, CI = confidence interval of OR, Chr = chromosome</p></div><div id="TFN6"><sup>a</sup>SNPs were selected based on their univariate meta-analysis p-values and the SNPs with the lowest p-values are shown. These SNPs had the lowest p-values among the 5051 typed SNPs and 10195 imputed SNPs with a p-value &lt;0.05 in each cohort separately and with concordant direction (effect) in the two cohorts. When there were multiple SNPs in LD only the one with the lowest p-value is represented</div><div id="TFN7"><sup>b</sup>imputed SNP</div><div id="TFN8"><sup>c</sup>including genetically defined ancestry and cumulative VCR dosage as covariates</div></div></div><p id="P24">Twenty of 32 patients (62%) with the TT genotype in the St. Jude cohort and 8 of 18 patients (44%) with the TT genotype in the COG cohort developed at least one episode of vincristine-induced neuropathy. In total, 28 out of 50 patients (56%) with the TT genotype developed at least one episode of grade 2–4 vincristine-induced neuropathy (<a href="/pmc/articles/PMC4377066/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>), compared to 58 of 271 patients (21.4%) with the CC or CT genotype (<em>p</em>=2.4×10<sup>−6</sup>). The allelic odds ratio for the development of neuropathy for rs924607 was 2.43 (95% CI: 1.70–3.49) and 4.1 (95% CI: 1.86–9.01) in the St. Jude and COG cohorts, respectively. As summarized in <a href="#SD1" rid="SD1" class=" supplementary-material">eTable 6</a>, the frequency of the <em>CEP72</em> risk allele (T) differed by ancestry, with a lower frequency in African ancestry patients and in the Hapmap cells from individuals of African ancestry (Yoruba in Ibadan, Nigeria; African ancestry in Southwest USA; Luhva in Webuve, Kenya; Maasai in Kinyama, Kenya,), compared to cells from individuals of European ancestry.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Vincristine-induced peripheral neuropathy and rs924607 genotype</strong><p id="__p29">The number of patients (n) for each rs924607 genotype and at each grade of vincristine-induced neuropathy are presented for the St. Jude Total XIIIB cohort (a), for the COG AALL0433 cohort (b), and for the combined cohort (c). Patients who experienced more than one episode of neuropathy at different grades were included at the highest grade reported.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140661515750240" class="xtable"><table frame="below" rules="groups" class="rendered small default_table"><thead><tr><th colspan="8" rowspan="1" valign="bottom" align="left">a. St Jude Total XIIIB
<hr></th></tr><tr><th rowspan="1" colspan="1" valign="middle" align="left">Patients</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 0 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 1 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 2 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 3 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 4 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Total (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">% with Grade 2–4 Vincristine Neuropathy</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>CC genotype</strong></td><td rowspan="1" colspan="1" valign="top" align="center">65</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">17</td><td rowspan="1" colspan="1" valign="top" align="center">8</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">91</td><td rowspan="1" colspan="1" valign="top" align="center">28.6</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>CT genotype</strong></td><td rowspan="1" colspan="1" valign="top" align="center">81</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">9</td><td rowspan="1" colspan="1" valign="top" align="center">9</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">99</td><td rowspan="1" colspan="1" valign="top" align="center">18.2</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>TT genotype</strong></td><td rowspan="1" colspan="1" valign="top" align="center">12</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">13</td><td rowspan="1" colspan="1" valign="top" align="center">7</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">32</td><td rowspan="1" colspan="1" valign="top" align="center">62.5</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>Total</strong></td><td rowspan="1" colspan="1" valign="top" align="center">158</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">39</td><td rowspan="1" colspan="1" valign="top" align="center">24</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">222</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr></tbody></table></div><div id="largeobj_idm140661515750240" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4377066/table/T3/?report=objectonly">Open in a separate window</a></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140661439494992" class="xtable"><table frame="below" rules="groups" class="rendered small default_table"><thead><tr><th colspan="8" rowspan="1" valign="bottom" align="left">b. COG AALL0433
<hr></th></tr><tr><th rowspan="1" colspan="1" valign="middle" align="left">Patients</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 0 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 1 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 2 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 3 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 4 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Total (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">% with Grade 2–4 Vincristine Neuropathy</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>CC genotype</strong></td><td rowspan="1" colspan="1" valign="top" align="center">37</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">4</td><td rowspan="1" colspan="1" valign="top" align="center">3</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">45</td><td rowspan="1" colspan="1" valign="top" align="center">15.6</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>CT genotype</strong></td><td rowspan="1" colspan="1" valign="top" align="center">28</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">4</td><td rowspan="1" colspan="1" valign="top" align="center">3</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">36</td><td rowspan="1" colspan="1" valign="top" align="center">19.4</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>TT genotype</strong></td><td rowspan="1" colspan="1" valign="top" align="center">9</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">3</td><td rowspan="1" colspan="1" valign="top" align="center">5</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">18</td><td rowspan="1" colspan="1" valign="top" align="center">44.4</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>Total</strong></td><td rowspan="1" colspan="1" valign="top" align="center">74</td><td rowspan="1" colspan="1" valign="top" align="center">3</td><td rowspan="1" colspan="1" valign="top" align="center">11</td><td rowspan="1" colspan="1" valign="top" align="center">11</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">99</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr></tbody></table></div><div id="largeobj_idm140661439494992" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4377066/table/T3/?report=objectonly">Open in a separate window</a></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140661435795584" class="xtable"><table frame="below" rules="groups" class="rendered small default_table"><thead><tr><th colspan="8" rowspan="1" valign="bottom" align="left">c. Combined cohort of St Jude Total XIIIB and COG AALL0433
<hr></th></tr><tr><th rowspan="1" colspan="1" valign="middle" align="left">Patients</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 0 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 1 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 2 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 3 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Grade 4 (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">Total (n)</th><th rowspan="1" colspan="1" valign="middle" align="center">% with Grade 2–4 Vincristine Neuropathy</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>CC genotype</strong></td><td rowspan="1" colspan="1" valign="top" align="center">102</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">21</td><td rowspan="1" colspan="1" valign="top" align="center">11</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">136</td><td rowspan="1" colspan="1" valign="top" align="center">24.3</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>CT genotype</strong></td><td rowspan="1" colspan="1" valign="top" align="center">109</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">13</td><td rowspan="1" colspan="1" valign="top" align="center">12</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">135</td><td rowspan="1" colspan="1" valign="top" align="center">18.5</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>TT genotype</strong></td><td rowspan="1" colspan="1" valign="top" align="center">21</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">16</td><td rowspan="1" colspan="1" valign="top" align="center">12</td><td rowspan="1" colspan="1" valign="top" align="center">0</td><td rowspan="1" colspan="1" valign="top" align="center">50</td><td rowspan="1" colspan="1" valign="top" align="center">56.0</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><strong>Total</strong></td><td rowspan="1" colspan="1" valign="top" align="center">232</td><td rowspan="1" colspan="1" valign="top" align="center">3</td><td rowspan="1" colspan="1" valign="top" align="center">50</td><td rowspan="1" colspan="1" valign="top" align="center">35</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">321</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr></tbody></table></div><div id="largeobj_idm140661435795584" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4377066/table/T3/?report=objectonly">Open in a separate window</a></div></div><p id="P25" class="p p-last">Because rs924607 is an imputed SNP, we validated the genotype in a subset of 30 patients, randomly chosen from patients to represent the three diplotypes for <em>CEP72</em>. This documented complete concordance between the imputed genotypes and those obtained by direct genotyping. (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 4</a>)</p></div><div id="S18" class="sec"><h3 id="S18title">Association of <em>CEP72</em> rs924607 genotype with development, onset time, and severity of vincristine-induced peripheral neuropathy</h3><p id="P26" class="p p-first">The cumulative incidence of all neuropathy episodes (grade 2–4) differed significantly by <em>CEP72</em> rs924607 genotype (diplotype) in both patient cohorts treated with 1.5 mg/m<sup>2</sup> of vincristine, with <em>p</em>-values in the St. Jude, the COG, and the combined cohorts of <em>p</em>&lt;0.0001, <em>p</em>=0.0087 and <em>p</em>&lt;0.0001 respectively (Gray’s test; <a href="/pmc/articles/PMC4377066/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2a–c</span></a>). Likewise, the cumulative incidence of severe neuropathy episodes (grades 3–4) was also significantly higher in patients homozygous for the <em>CEP72</em> risk allele (<a href="/pmc/articles/PMC4377066/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2d</span></a>; <em>p</em>&lt;0.0001). Simply based on binomial proportions, 21 of 38 (55.3% [95% CI 39.7%–69.9%]) patients with the <em>CEP72</em> TT genotype experienced grade 2–4 neuropathy over the monitoring period compared to 46 of 235 (19.6% [95% CI 14.8%–25.3%]) patients with the CC/CT genotype (<em>p</em>&lt;0.001). The cumulative incidence of the first neuropathy episode (grade 2–4) was 60.8% (95% CI 43.9%–77.6%) among patients with the <em>CEP72</em> TT genotype compared to 23.4% (95% CI 17.4%–29.4%) among patients with the CC/CT genotype (p&lt;0.001). The risk of developing neuropathy was significantly higher in patients with the <em>CEP72</em> TT genotype (TT vs. CT/CC hazard ratio of 3.58, 95% CI 2.1, 6.1 for TT compared to the CT/CC patients) in a Cox regression model adjusting for cumulative vincristine dosage and genetically determined ancestry (<a href="#SD1" rid="SD1" class=" supplementary-material">eTable 7</a>). This <em>CEP72</em> SNP was not significantly associated with the incidence of vincristine-induced neuropathy among patients randomized to treatment with the higher (experimental) dosage of vincristine (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 5</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC4377066/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140661443868032" class="figure"><a href="/pmc/articles/PMC4377066/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4377066_nihms667277f2.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms667277f2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC4377066/bin/nihms667277f2.jpg"></a></div><div id="largeobj_idm140661443868032" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4377066/figure/F2/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC4377066/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p18">Cumulative incidence of vincristine-induced neuropathy among patients with different <em>CEP72</em> genotypes. The cumulative incidence of vincristine-induced neuropathy (grades 2–4) differed by <em>CEP72</em> promoter SNP (rs924607) genotype in the St Jude cohort (a) (<em>p</em>&lt; 0.0001), the COG cohort group A (b) (<em>p</em> =0.0087) and in the combined St Jude and COG group A cohort (c) (<em>p</em> &lt;0.0001). Likewise, the cumulative incidence of severe neuropathy (grades 3–4) was also significantly higher in patients homozygous for the <em>CEP72</em> risk allele (d). P values were computed based on weighted logistic regression adjusting for ancestry and accounting for multiple episodes of neuropathy. The number of patients valuable and at risk of neuropathy is provided for each <em>CEP72</em> genotype (diplotype). The x-axis represents time since the start of continuation therapy for ALL.</p></div></div></div><p id="P27">By fitting an accelerated failure time model<sup><a href="#R22" rid="R22" class=" bibr popnode">22</a></sup> with <em>CEP72</em> genotype, cumulative vincristine dosage and genetically-determined ancestry as explanatory variables, the estimated ratio of median time to the first episode of neuropathy in TT patients compared to patients with a CT or CC genotype was approximately 20% shorter in TT patients within any race and at any cumulative vincristine dosage level (<em>p</em>-value = 6.19×10<sup>−6</sup> for the regression coefficient of the SNP) (<a href="#SD1" rid="SD1" class=" supplementary-material">eTable 8</a>). Without adjusting for covariates, among those who developed grade 2–4 neuropathy, the average time to develop neuropathy was 225 days (95% CI: 169–281 days) in patients with the <em>CEP72</em> genotype TT compared to 307 days in patients with the CT/CC genotype (95% CI: 244–370 days).</p><p id="P28" class="p p-last">In unadjusted analysis comparing the average grade of neuropathy observed at the first episode (assigning grade 0 to those who did not develop neuropathy) in patients treated with 1.5 mg/m<sup>2</sup> vincristine, the mean grade of neuropathy in white patients with the <em>CEP72</em> high-risk genotype (TT) was significantly higher (2.7-fold) than the mean grade of neuropathy in patients with the CEP72 CC or CT genotypes (1.23 [95% CI 0.74 – 1.72] versus 0.45 [95% CI 0.3 – 0.6]; t test p=0.004). The numbers of patients in other ancestry groups were too small to make meaningful subgroup comparisons. Using the Poisson regression model to assess the severity (grade) of neuropathy at first episode, with genetically defined ancestry and cumulative vincristine dosage as covariates in the combined cohort, the average grade (by CTCAE) of neuropathy was 2.4-fold greater (95% CI 1.59–3.69) in patients homozygous for the <em>CEP72</em> risk allele (TT) compared to all other patients (<em>p</em>&lt;0.0001; <a href="#SD1" rid="SD1" class=" supplementary-material">eTable 9</a>).</p></div><div id="S19" class="sec"><h3 id="S19title">Rs924607 and <em>CEP72</em> mRNA expression</h3><p id="P29" class="p p-first-last">Because rs924607 is located in the promoter region of <em>CEP72</em>, we examined <em>CEP72</em> mRNA expression levels for association with rs924607 genotype in Hapmap samples (CEU), using the publicly available gene expression data set<sup><a href="#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760765">24</a></sup>. Patients who were homozygous for the variant T-allele had significantly lower expression of <em>CEP72</em> mRNA compared to those who were heterozygous or homozygous for the wild-type C-allele (<em>p</em>=0.025, <a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 6a</a>). The effect of rs924607 genotype on <em>CEP72</em> expression was confirmed using a luciferase reporter assay in two different human cell lines, documenting significantly lower expression with the T-allele compared to the C-allele in both SH-SY5Y neuroblastoma cells (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 6b</a>) and in Nalm6 leukemia cells (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 6c</a>). The rs924607 T variant creates a consensus binding site for the NKX-6.3 transcription factor (repressor) (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigures 6d and 6e</a>, <a href="#SD1" rid="SD1" class=" supplementary-material">eTable 10</a>; <a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 6f, 6g, 6h</a>), markedly enhancing NKX-6.3 binding to the risk allele, leading to lower <em>CEP72</em> mRNA expression.</p></div><div id="S20" class="sec sec-last"><h3 id="S20title">Low <em>CEP72</em> expression and vincristine-induced toxicity</h3><p id="P30" class="p p-first">The relationship between <em>CEP72</em> expression and vincristine-induced neurotoxicity was assessed in neurons derived from human induced pluripotent stem cells (iPSC), revealing significantly greater sensitivity to vincristine when <em>CEP72</em> expression was reduced (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 7a, 7b</a>).</p><p id="P31" class="p p-last">Likewise, reducing expression of <em>CEP72</em> in two human ALL cells lines, Nalm6 (B-lineage) (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 7c</a>) and CEM (T-lineage) (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 7e</a>), was associated with increased sensitivity to vincristine (<a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 7d, 7f</a>). Moreover, primary leukemia cells from newly diagnosed patients who were homozygous for the <em>CEP72</em> risk allele (TT) (mean LC<sub>50</sub> = 0.9 μM, 95% CI −0.5 – 2.3 μM) were more sensitive to vincristine when compared to patients with either the CT (mean LC<sub>50</sub> = 2.6 μM, 95% CI 0.6 – 4.7 μM) or CC (mean LC<sub>50</sub> = 11.9 μM, 95% CI 3.0 – 20.7 μM) <em>CEP72</em> genotype (<em>p</em>=0.016, <a href="#SD1" rid="SD1" class=" supplementary-material">eFigure 7g</a>).</p></div></div><div id="S21" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S21title">Discussion</h2><p id="P32" class="p p-first">We found that an inherited variant in the promoter region of the <em>CEP72</em> gene was associated with a higher incidence and severity of vincristine-related peripheral neuropathy in children with ALL, with the cumulative incidence of neuropathy significantly higher and the average grade of neuropathy significantly greater in patients homozygous for the <em>CEP72</em> risk allele (TT) compared to all other patients. The <em>CEP72</em> gene encodes a centrosomal protein that is essential for microtubule formation, and vincristine exerts its pharmacologic effects by inhibiting microtubule formation. We found that the <em>CEP72</em> variant associated with vincristine neuropathy (T allele at rs924607) creates a binding site for a transcriptional repressor, leading to lower <em>CEP72</em> mRNA expression, and we showed that reducing the expression of <em>CEP72</em> in human iPSC neurons or leukemia cells increased their sensitivity to vincristine. Because vincristine-induced toxicities can be influenced by cumulative dosage of vincristine and differ by race, we included both cumulative dosage and ancestry as covariates in our analyses, revealing that the <em>CEP72</em> rs924607SNP was the only SNP reaching genome-wide significance (&lt;5×10<sup>−8</sup>) in its association with vincristine-induced neuropathy. The frequency of the risk allele (T) was lower in African-American patients compared to the other racial groups, consistent with its lower frequency in African ancestry samples in the Hapmap collection. This finding is also consistent with the reported lower incidence of vincristine-induced neuropathy in black patients<sup><a href="#R25" rid="R25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760769">25</a></sup>. We found that children who inherited two copies of the <em>CEP72</em> risk allele (homozygous for T at rs924607) had a significantly higher incidence of vincristine-induced peripheral neuropathy (60.8% [95% CI 43.9%–77.6% in TT patients compared to 23.4% [95% CI 17.4%–29.4] in CC/CT patients). We also found that <em>CEP72</em> TT patients had increased severity (grade) of toxicity at first episode (2.4 fold higher grade of neuropathy; 95% CI 1.6–3.7 for TT compared to CT/CC patients) at any given cumulative dosage of vincristine.</p><p id="P33">Vincristine is widely used to treat leukemia, lymphoma, various solid tumors and brain tumors in children and adults<sup><a href="#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760751">26</a></sup>. Vincristine-induced peripheral neuropathy, characterized by sensory and motor dysfunction, causes extensive morbidity and often disrupts treatment. In children with ALL, the reported incidence of vincristine-induced neuropathy differs across treatment protocols, due in part to the grade of toxicity considered<sup><a href="#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760756">27</a>,<a href="#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760774">28</a></sup>, the VCR dosage and number of doses given<sup><a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760760">29</a></sup>, and the types of symptoms captured<sup><a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760764">9</a></sup>. In the current study, patients received uniform treatment according to prospective clinical trials, with neuropathy assessed by NCI criteria to prospectively identify all patients who developed grades 2–4 neuropathy during continuation therapy with vincristine. Although a genetic component of vincristine-induced neuropathy would be consistent with previously reported racial differences in the incidence of vincristine-induced neuropathy<sup><a href="#R25" rid="R25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_438760768">25</a></sup>, previous candidate gene studies have not yielded reproducible findings. We therefore took an agnostic genome-wide approach to identify genetic variants influencing vincristine-induced peripheral neuropathy, revealing the previously unrecognized association with <em>CEP72</em> genotype.</p><p id="P34" class="p p-last">The current study has limitations, including the small sample size (n=321), the small number of patients homozygous for the <em>CEP72</em> risk allele (~16% of patients, n=50), and our assessment of only children in the context of ALL chemotherapy. However, our clinical findings are corroborated by multiple lines of laboratory evidence in human iPSC neurons and leukemia cells, and if verified in additional patient populations, could lead to a new approach for identifying patients at high-risk of vincristine-related neuropathy. Because our data suggest that the leukemia cells of patients who are homozygous for the CEP72 risk allele are more sensitive to vincristine, it may be possible to treat these patients with a lower dosage of vincristine to decrease the risk or severity of neuropathy without compromising the antileukemic effects of vincristine, a possibility that merits assessment in future clinical trials.</p></div><div id="S22" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S22title">Conclusion</h2><p id="P35" class="p p-first-last">In this preliminary study of children with ALL, an inherited polymorphism in the promoter region of <em>CEP72</em> was associated with increased risk and severity of vincristine-related peripheral neuropathy. If replicated in additional populations, this finding may provide a basis for safer dosing of this widely prescribed anticancer agent.</p></div><div id="S23" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S23title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>Supplemental Materials</h4><div class="sup-box half_rhythm" id="d36e995"><a href="/pmc/articles/PMC4377066/bin/NIHMS667277-supplement-Supplemental_Materials.pdf" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(680K, pdf)</sup></div></div></div><div id="S24" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S24title">Acknowledgments</h2><div class="sec"><p id="__p1"><strong>Funding/Support</strong></p><p id="__p2">The study was supported in part by NIH Grants No. R37 CA36401 (W.E.E. and M.V.R.), U01 GM92666 (M.V.R., D.P., C.C., W.Y., S.P., M.L.L., M.D. and W.E.E.), UO1 GM61393 (M.E.D.), R01 CA136765 (M.E.D.) F32 <a id="__tag_781834482" class="tag_hotlink" href="/nuccore/CA165823" ref="/nuccore/CA165823"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"CA165823","term_id":"35084617","term_text":"CA165823"}}</span>CA165823</a> (H.E.W.), Comprehensive Cancer Center grant CA21765, U10 CA98543 (COG Chair’s grant), U10 CA98413 (COG Statistical Center), and U24 <a id="__tag_781834481" class="tag_hotlink" href="/nuccore/CA114766" ref="/nuccore/CA114766"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"CA114766","term_id":"34968073","term_text":"CA114766"}}</span>CA114766</a> (COG Specimen Banking) from the National Cancer Institute, and by the American Lebanese Syrian Associated Charities.</p></div></div><div id="idm140661515579104" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140661515579104title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><div><p id="__p3" class="p p-first"><strong>Additional Contributions</strong></p>We thank the St. Jude Hartwell Center for Bioinformatics and Biotechnology and the Flow Cytometry &amp; Cell Sorting Shared Resource of the St. Jude Children’s Research Hospital Comprehensive Cancer Center. We thank Kirsten Ness (PT, PhD) for her assistance with preparation of the online-only summary of NCI Common Toxicity Terminology for assessing neuropathy. We thank Jun Yang (PhD), Virginia Perez-Andreu (MD), Nancy Kornegay (MBA), Mark Wilkinson (BS), and Colton Smith (PhD) for their expertise and assistance in specific components of data analysis and Julie Groff (BA), Elizabeth Stevens and Joshua Stokes (BA) for preparation of Figures, and Caleb Simmons (BA) for the preparation of the manuscript.</div><p class="fn sec" id="FN3"></p><p id="__p5" class="p p-first"><strong>Statement</strong></p><p id="__p6" class="p p-last">William E. Evans had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p></p><div><p id="__p7" class="p p-first"><strong>Author Contributions</strong></p><strong>Conception and design of the study:</strong> William E. Evans; Mary V. Relling<p id="__p9" class="p"><strong>Acquisition, analysis, or interpretation of data:</strong> Barthelemy Diouf; Kristine R. Crews; Glen Lew; Deqing Pei; Cheng Cheng; Ju Bao; Jie J. Zheng; Wenjian Yang; Yiping Fan; Heather E. Wheeler; Claudia Wing; Shannon M. Delaney; Masaaki Komatsu; Steven W. Paugh; Joseph Robert McCorkle; Xiaomin Lu; Naomi J. Winick; William L. Carroll; Mignon L. Loh; Stephen P. Hunger; Meenakshi Devidas; Ching-Hon Pui; M. Eileen Dolan; Mary V. Relling and William E. Evans</p><p id="__p10" class="p"><strong>Drafting of the manuscript:</strong> Barthelemy Diouf, Kristine Crews, Ching-Hon Pui, Cheng Cheng, William E. Evans</p><p id="__p11" class="p"><strong>Critical revision of the manuscript for important intellectual content:</strong> Barthelemy Diouf; Kristine R. Crews; Glen Lew; Deqing Pei; Cheng Cheng; Ju Bao; Jie J. Zheng; Wenjian Yang; Yiping Fan; Heather E. Wheeler; Claudia Wing; Shannon M. Delaney; Masaaki Komatsu; Steven W. Paugh; Joseph Robert McCorkle; Xiaomin Lu; Naomi J. Winick; William L. Carroll; Mignon L. Loh; Stephen P. Hunger; Meenakshi Devidas; Ching-Hon Pui; M. Eileen Dolan; Mary V. Relling and William E. Evans</p><p id="__p12" class="p"><strong>Statistical analysis:</strong> Deqing Pei; Cheng Cheng;</p><p id="__p13" class="p"><strong>Obtaining funding:</strong> William E. Evans, Mary V. Relling, Stephen P. Hunger.</p><p id="__p14" class="p"><strong>Supervision:</strong> William E. Evans</p><p id="__p15" class="p p-last"><strong>Conflict of Interest Disclosures:</strong> The authors declare no competing financial interests.</p></div><p class="fn sec" id="FN5"></p><p id="__p16" class="p p-first-last"><strong>Role of the Sponsors:</strong> None of the funding sources played any role in the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation, review, or approval of the manuscript.</p><p></p></div></div><div id="idm140661438627200" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140661438627200title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="element-citation">Pui CH, Evans WE. Acute lymphoblastic leukemia. <span><span class="ref-journal">The New England journal of medicine. </span>1998;<span class="ref-vol">339</span>(9):605–615.</span> [<a href="/pubmed/9718381" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+New+England+journal+of+medicine&amp;title=Acute+lymphoblastic+leukemia&amp;author=CH+Pui&amp;author=WE+Evans&amp;volume=339&amp;issue=9&amp;publication_year=1998&amp;pages=605-615&amp;pmid=9718381&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="element-citation">Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. <span><span class="ref-journal">The New England journal of medicine. </span>2006;<span class="ref-vol">354</span>(2):166–178.</span> [<a href="/pubmed/16407512" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+New+England+journal+of+medicine&amp;title=Treatment+of+acute+lymphoblastic+leukemia&amp;author=CH+Pui&amp;author=WE+Evans&amp;volume=354&amp;issue=2&amp;publication_year=2006&amp;pages=166-178&amp;pmid=16407512&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="element-citation">Pizzo PA, Poplack DG.  <span class="ref-journal">Principles and Practice of Pediatric Oncology.</span> 6 Wolters Kluwer/Lippincott Williams&amp;Wilkins; 2011.  <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Principles+and+Practice+of+Pediatric+Oncology&amp;author=PA+Pizzo&amp;author=DG+Poplack&amp;publication_year=2011&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="element-citation">Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. <span><span class="ref-journal">Proceedings of the National Academy of Sciences of the United States of America. </span>1993;<span class="ref-vol">90</span>(20):9552–9556.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC47607/">PMC free article</a>]</span> [<a href="/pubmed/8105478" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;title=Mechanism+of+mitotic+block+and+inhibition+of+cell+proliferation+by+taxol+at+low+concentrations&amp;author=MA+Jordan&amp;author=RJ+Toso&amp;author=D+Thrower&amp;author=L+Wilson&amp;volume=90&amp;issue=20&amp;publication_year=1993&amp;pages=9552-9556&amp;pmid=8105478&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="element-citation">Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. <span><span class="ref-journal">Nature reviews Cancer. </span>2004;<span class="ref-vol">4</span>(4):253–265.</span> [<a href="/pubmed/15057285" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+reviews+Cancer&amp;title=Microtubules+as+a+target+for+anticancer+drugs&amp;author=MA+Jordan&amp;author=L+Wilson&amp;volume=4&amp;issue=4&amp;publication_year=2004&amp;pages=253-265&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="element-citation">Toh HC, Sun L, Koh CH, Aw SE. Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristine. <span><span class="ref-journal">Leukemia &amp; lymphoma. </span>1998;<span class="ref-vol">31</span>(1–2):195–208.</span> [<a href="/pubmed/9720729" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia+&amp;+lymphoma&amp;title=Vinorelbine+induces+apoptosis+and+caspase-3+(CPP32)+expression+in+leukemia+and+lymphoma+cells:+a+comparison+with+vincristine&amp;author=HC+Toh&amp;author=L+Sun&amp;author=CH+Koh&amp;author=SE+Aw&amp;volume=31&amp;issue=1–2&amp;publication_year=1998&amp;pages=195-208&amp;pmid=9720729&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="element-citation">Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. <span><span class="ref-journal">Journal of the neurological sciences. </span>1970;<span class="ref-vol">10</span>(2):107–131.</span> [<a href="/pubmed/4314181" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+the+neurological+sciences&amp;title=The+neuromyopathy+of+vincristine+in+man.+Clinical,+electrophysiological+and+pathological+studies&amp;author=WG+Bradley&amp;author=LP+Lassman&amp;author=GW+Pearce&amp;author=JN+Walton&amp;volume=10&amp;issue=2&amp;publication_year=1970&amp;pages=107-131&amp;pmid=4314181&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="element-citation">Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS. Vincristine pharmacokinetics after repetitive dosing in children. <span><span class="ref-journal">Cancer chemotherapy and pharmacology. </span>1999;<span class="ref-vol">44</span>(3):203–209.</span> [<a href="/pubmed/10453721" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+chemotherapy+and+pharmacology&amp;title=Vincristine+pharmacokinetics+after+repetitive+dosing+in+children&amp;author=CE+Gidding&amp;author=GJ+Meeuwsen-de+Boer&amp;author=P+Koopmans&amp;author=DR+Uges&amp;author=WA+Kamps&amp;volume=44&amp;issue=3&amp;publication_year=1999&amp;pages=203-209&amp;pmid=10453721&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="element-citation">Egbelakin A, Ferguson MJ, MacGill EA, et al.  Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. <span><span class="ref-journal">Pediatric blood &amp; cancer. </span>2011;<span class="ref-vol">56</span>(3):361–367.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3020258/">PMC free article</a>]</span> [<a href="/pubmed/21225912" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pediatric+blood+&amp;+cancer&amp;title=Increased+risk+of+vincristine+neurotoxicity+associated+with+low+CYP3A5+expression+genotype+in+children+with+acute+lymphoblastic+leukemia&amp;author=A+Egbelakin&amp;author=MJ+Ferguson&amp;author=EA+MacGill&amp;volume=56&amp;issue=3&amp;publication_year=2011&amp;pages=361-367&amp;pmid=21225912&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="element-citation">Aplenc R, Glatfelter W, Han P, et al.  CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. <span><span class="ref-journal">British journal of haematology. </span>2003;<span class="ref-vol">122</span>(2):240–244.</span> [<a href="/pubmed/12846892" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=British+journal+of+haematology&amp;title=CYP3A+genotypes+and+treatment+response+in+paediatric+acute+lymphoblastic+leukaemia&amp;author=R+Aplenc&amp;author=W+Glatfelter&amp;author=P+Han&amp;volume=122&amp;issue=2&amp;publication_year=2003&amp;pages=240-244&amp;pmid=12846892&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="element-citation">Ross CJ, Visscher H, Rassekh SR, et al.  Pharmacogenomics of serious adverse drug reactions in pediatric oncology. <span><span class="ref-journal">Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique. </span>2011;<span class="ref-vol">18</span>:e134–151.</span> [<a href="/pubmed/21467604" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+population+therapeutics+and+clinical+pharmacology+=+Journal+de+la+therapeutique+des+populations+et+de+la+pharamcologie+clinique&amp;title=Pharmacogenomics+of+serious+adverse+drug+reactions+in+pediatric+oncology&amp;author=CJ+Ross&amp;author=H+Visscher&amp;author=SR+Rassekh&amp;volume=18&amp;publication_year=2011&amp;pages=e134-151&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="element-citation">Plasschaert SL, Groninger E, Boezen M, et al.  Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. <span><span class="ref-journal">Clinical pharmacology and therapeutics. </span>2004;<span class="ref-vol">76</span>(3):220–229.</span> [<a href="/pubmed/15371983" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+pharmacology+and+therapeutics&amp;title=Influence+of+functional+polymorphisms+of+the+MDR1+gene+on+vincristine+pharmacokinetics+in+childhood+acute+lymphoblastic+leukemia&amp;author=SL+Plasschaert&amp;author=E+Groninger&amp;author=M+Boezen&amp;volume=76&amp;issue=3&amp;publication_year=2004&amp;pages=220-229&amp;pmid=15371983&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="element-citation">Pui CH, Sandlund JT, Pei D, et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">104</span>(9):2690–2696.</span> [<a href="/pubmed/15251979" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Improved+outcome+for+children+with+acute+lymphoblastic+leukemia:+results+of+Total+Therapy+Study+XIIIB+at+St+Jude+Children’s+Research+Hospital&amp;author=CH+Pui&amp;author=JT+Sandlund&amp;author=D+Pei&amp;volume=104&amp;issue=9&amp;publication_year=2004&amp;pages=2690-2696&amp;pmid=15251979&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="element-citation">Pui CH, Campana D, Pei D, et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. <span><span class="ref-journal">The New England journal of medicine. </span>2009;<span class="ref-vol">360</span>(26):2730–2741.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2754320/">PMC free article</a>]</span> [<a href="/pubmed/19553647" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+New+England+journal+of+medicine&amp;title=Treating+childhood+acute+lymphoblastic+leukemia+without+cranial+irradiation&amp;author=CH+Pui&amp;author=D+Campana&amp;author=D+Pei&amp;volume=360&amp;issue=26&amp;publication_year=2009&amp;pages=2730-2741&amp;pmid=19553647&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="element-citation">Kishi S, Cheng C, French D, et al.  Ancestry and pharmacogenetics of antileukemic drug toxicity. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>(10):4151–4157.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1885506/">PMC free article</a>]</span> [<a href="/pubmed/17264302" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Ancestry+and+pharmacogenetics+of+antileukemic+drug+toxicity&amp;author=S+Kishi&amp;author=C+Cheng&amp;author=D+French&amp;volume=109&amp;issue=10&amp;publication_year=2007&amp;pages=4151-4157&amp;pmid=17264302&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="element-citation">Trotti A, Colevas AD, Setser A, et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. <span><span class="ref-journal">Semin Radiat Oncol. </span>2003;<span class="ref-vol">13</span>(3):176–181.</span> [<a href="/pubmed/12903007" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Semin+Radiat+Oncol&amp;title=CTCAE+v3.0:+development+of+a+comprehensive+grading+system+for+the+adverse+effects+of+cancer+treatment&amp;author=A+Trotti&amp;author=AD+Colevas&amp;author=A+Setser&amp;volume=13&amp;issue=3&amp;publication_year=2003&amp;pages=176-181&amp;pmid=12903007&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="element-citation">Hudson MM, Ness KK, Gurney JG, et al.  Clinical ascertainment of health outcomes among adults treated for childhood cancer. <span><span class="ref-journal">JAMA. </span>2013;<span class="ref-vol">309</span>(22):2371–2381.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3771083/">PMC free article</a>]</span> [<a href="/pubmed/23757085" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Clinical+ascertainment+of+health+outcomes+among+adults+treated+for+childhood+cancer&amp;author=MM+Hudson&amp;author=KK+Ness&amp;author=JG+Gurney&amp;volume=309&amp;issue=22&amp;publication_year=2013&amp;pages=2371-2381&amp;pmid=23757085&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="element-citation">Cancer Therapy Evaluation Program (CTEP)  [Accessed November 21, 2014];<span><span class="ref-journal">National Cancer Institute website. </span></span>  <a href="http://dctd.cancer.gov/ProgramPages/CTEP/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://dctd.cancer.gov/ProgramPages/CTEP/</a></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="element-citation">Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. <span><span class="ref-journal">Genetic epidemiology. </span>2010;<span class="ref-vol">34</span>(8):816–834.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3175618/">PMC free article</a>]</span> [<a href="/pubmed/21058334" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genetic+epidemiology&amp;title=MaCH:+using+sequence+and+genotype+data+to+estimate+haplotypes+and+unobserved+genotypes&amp;author=Y+Li&amp;author=CJ+Willer&amp;author=J+Ding&amp;author=P+Scheet&amp;author=GR+Abecasis&amp;volume=34&amp;issue=8&amp;publication_year=2010&amp;pages=816-834&amp;pmid=21058334&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="element-citation">Yang JJ, Cheng C, Devidas M, et al.  Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. <span><span class="ref-journal">Nature genetics. </span>2011;<span class="ref-vol">43</span>(3):237–241.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3104508/">PMC free article</a>]</span> [<a href="/pubmed/21297632" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+genetics&amp;title=Ancestry+and+pharmacogenomics+of+relapse+in+acute+lymphoblastic+leukemia&amp;author=JJ+Yang&amp;author=C+Cheng&amp;author=M+Devidas&amp;volume=43&amp;issue=3&amp;publication_year=2011&amp;pages=237-241&amp;pmid=21297632&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="element-citation">Holleman A, Cheok MH, den Boer ML, et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">351</span>(6):533–542.</span> [<a href="/pubmed/15295046" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Gene-expression+patterns+in+drug-resistant+acute+lymphoblastic+leukemia+cells+and+response+to+treatment&amp;author=A+Holleman&amp;author=MH+Cheok&amp;author=ML+den+Boer&amp;volume=351&amp;issue=6&amp;publication_year=2004&amp;pages=533-542&amp;pmid=15295046&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="element-citation">Kalbfleisch JD, Prentice R.  <span class="ref-journal">The Statistical Analysis of Failure Time Data.</span> 2. Chapter 7 Wiley &amp; Sons Inc; New York: 2002.  <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=The+Statistical+Analysis+of+Failure+Time+Data&amp;author=JD+Kalbfleisch&amp;author=R+Prentice&amp;publication_year=2002&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="element-citation">Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. <span><span class="ref-journal">Ann Statist. </span>1988;<span class="ref-vol">16</span>:1141–1154.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Statist&amp;title=A+class+of+K-sample+tests+for+comparing+the+cumulative+incidence+of+a+competing+risk&amp;author=RJ+Gray&amp;volume=16&amp;publication_year=1988&amp;pages=1141-1154&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="element-citation">Huang RS, Duan S, Shukla SJ, et al.  Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. <span><span class="ref-journal">American journal of human genetics. </span>2007;<span class="ref-vol">81</span>(3):427–437.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1950832/">PMC free article</a>]</span> [<a href="/pubmed/17701890" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=American+journal+of+human+genetics&amp;title=Identification+of+genetic+variants+contributing+to+cisplatin-induced+cytotoxicity+by+use+of+a+genomewide+approach&amp;author=RS+Huang&amp;author=S+Duan&amp;author=SJ+Shukla&amp;volume=81&amp;issue=3&amp;publication_year=2007&amp;pages=427-437&amp;pmid=17701890&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="element-citation">Renbarger JL, McCammack KC, Rouse CE, Hall SD. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. <span><span class="ref-journal">Pediatric blood &amp; cancer. </span>2008;<span class="ref-vol">50</span>(4):769–771.</span> [<a href="/pubmed/18085684" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pediatric+blood+&amp;+cancer&amp;title=Effect+of+race+on+vincristine-associated+neurotoxicity+in+pediatric+acute+lymphoblastic+leukemia+patients&amp;author=JL+Renbarger&amp;author=KC+McCammack&amp;author=CE+Rouse&amp;author=SD+Hall&amp;volume=50&amp;issue=4&amp;publication_year=2008&amp;pages=769-771&amp;pmid=18085684&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="element-citation">Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. <span><span class="ref-journal">Pharmacology &amp; therapeutics. </span>1991;<span class="ref-vol">52</span>(1):35–84.</span> [<a href="/pubmed/1687171" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacology+&amp;+therapeutics&amp;title=The+clinical+pharmacology+and+use+of+antimicrotubule+agents+in+cancer+chemotherapeutics&amp;author=EK+Rowinsky&amp;author=RC+Donehower&amp;volume=52&amp;issue=1&amp;publication_year=1991&amp;pages=35-84&amp;pmid=1687171&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="element-citation">Aytac S, Yetgin S, Tavil B. Acute and long-term neurologic complications in children with acute lymphoblastic leukemia. <span><span class="ref-journal">The Turkish journal of pediatrics. </span>2006;<span class="ref-vol">48</span>(1):1–7.</span> [<a href="/pubmed/16562778" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Turkish+journal+of+pediatrics&amp;title=Acute+and+long-term+neurologic+complications+in+children+with+acute+lymphoblastic+leukemia&amp;author=S+Aytac&amp;author=S+Yetgin&amp;author=B+Tavil&amp;volume=48&amp;issue=1&amp;publication_year=2006&amp;pages=1-7&amp;pmid=16562778&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="element-citation">Crom WR, de Graaf SS, Synold T, et al.  Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. <span><span class="ref-journal">The Journal of pediatrics. </span>1994;<span class="ref-vol">125</span>(4):642–649.</span> [<a href="/pubmed/7931891" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Journal+of+pediatrics&amp;title=Pharmacokinetics+of+vincristine+in+children+and+adolescents+with+acute+lymphocytic+leukemia&amp;author=WR+Crom&amp;author=SS+de+Graaf&amp;author=T+Synold&amp;volume=125&amp;issue=4&amp;publication_year=1994&amp;pages=642-649&amp;pmid=7931891&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="element-citation">Pal PK. Clinical and electrophysiological studies in vincristine induced neuropathy. <span><span class="ref-journal">Electromyography and clinical neurophysiology. </span>1999;<span class="ref-vol">39</span>(6):323–330.</span> [<a href="/pubmed/10499201" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Electromyography+and+clinical+neurophysiology&amp;title=Clinical+and+electrophysiological+studies+in+vincristine+induced+neuropathy&amp;author=PK+Pal&amp;volume=39&amp;issue=6&amp;publication_year=1999&amp;pages=323-330&amp;pmid=10499201&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4377066&amp;issue-id=251122&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="#ui-ncbiinpagenav-heading-3">Associated Data</a></li><li><a href="#idm140661515613664title">Abstract</a></li><li><a href="#S8title">Introduction</a></li><li><a href="#S9title">Methods</a></li><li><a href="#S14title">Results</a></li><li><a href="#S21title">Discussion</a></li><li><a href="#S22title">Conclusion</a></li><li><a href="#S23title">Supplementary Material</a></li><li><a href="#S24title">Acknowledgments</a></li><li><a href="#idm140661515579104title">Footnotes</a></li><li><a href="#idm140661438627200title">References</a></li></ul></div></div><!--post-content--></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC4377066/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC4377066/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC4377066/pdf/nihms667277.pdf">PDF (414K)</a></li> | <li><a href="#" data-citationid="PMC4377066" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4377066%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4377066%2F&amp;text=Association%20of%20an%20inherited%20genetic%20variant%20with%20vincristine-related%20peripheral%20neuropathy%20in%20children%20with%20acute%20lymphoblastic%20leukemia" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4377066%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="25710658" data-aiid="4377066" data-aid="4377066" data-iid="251122" data-domainid="319" data-domain="nihpa" data-accid="PMC4377066" data-md5="ef0f2f99eb5bb5487c08734fa75a947b"><img src="/portal/portal3rc.fcgi/4018218/img/3631476" alt="Loading..." align="absmiddle"> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-11-20T13:25:37-05:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=portal105&amp;ncbi_phid=CE8C2C6ADD580B110000000002EA01AD&amp;ncbi_session=CE8C6010DD4F8B31_0740SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4377066%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 68.1px; left: 377.2px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC4377066/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C6010DD4F8B31_0740SID /projects/PMC/PMCViewer@4.46 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></html>